Concepedia

Author

Massimiliano Salati

University of Modena and Reggio EmiliaORCID

Also Known As

M Salati, M. Salati, Massimiliano Salati, Michele Sacco, Salati,Massimiliano

115

Publications

1.9K

Citations

22

H-Index

33

Concepts

All Affiliations

University of Modena and Reggio EmiliaIstituti di Ricovero e Cura a Carattere ScientificoFondazione IRCCS Istituto Nazionale dei TumoriIstituto Oncologico VenetoAzienda Ospedaliera Universitaria Pisana
MS

About

Massimiliano Salati is an author at University of Modena and Reggio Emilia specializing in oncology, medicine, and radiation oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

10

10

290

2

Health Sciences

1

1

17

3

Public Health

1

1

38

4

Cell Biology

1

1

10

5

Epidemiology

1

1

38

Massimiliano Salati

×

29

Publications

914

Citations

18

H-Index

YearCitations

Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers

Giovanni Fucà, Romain Cohen, Sara Lonardi,

Journal for ImmunoTherapy of Cancer

2022

107

The Pan-Immune-Inflammation Value in microsatellite instability–high metastatic colorectal cancer patients treated with immune checkpoint inhibitors

Francesca Corti, Sara Lonardi, Rossana Intini,

European Journal of Cancer

2021

102

A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab

Andrea Botticelli, Massimiliano Salati, Francesca Romana Di Pietro,

Journal of Translational Medicine

2019

63

Assessing the impact of COVID-19 on liver cancer management (CERO-19)

Sergio Muñoz, Víctor Sapena, Alejandro Forner,

JHEP Reports

2021

60

The prognostic nutritional index predicts survival and response to first‐line chemotherapy in advanced biliary cancer

Massimiliano Salati, Roberto Filippi, Caterina Vivaldi,

Liver International

2019

57

Stevens–Johnson syndrome during nivolumab treatment of NSCLC

Massimiliano Salati, Massimo Pifferi, Cinzia Baldessari,

Annals of Oncology

2017

53

Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Microsatellite Instability-High End-Stage Cancers and Poor Performance Status Related to High Disease Burden

Filippo Pietrantonio, Fotios Loupakis, Giovanni Randon,

The Oncologist

2020

50

EGFR amplification and outcome in a randomised phase III trial of chemotherapy alone or chemotherapy plus panitumumab for advanced gastro-oesophageal cancers

Elizabeth Smyth, Georgios Vlachogiannis, Somaieh Hedayat,

Gut

2020

41

Cancer incidence, mortality, and survival in Eastern Libya: updated report from the Benghazi Cancer Registry

Mufid El Mistiri, Massimiliano Salati, Luigi Marcheselli,

Annals of Epidemiology

2015

38

Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience

Alessandra Boccaccino, Beatrice Borelli, Rossana Intini,

ESMO Open

2022

31

Page 1